---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-045308"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:40:19.770325+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Michael Severino to step down as AbbVie Vice Chairman and President, effective May 31, 2022

## Summary
- Michael E. Severino will depart as Vice Chairman and President of AbbVie, effective May 31, 2022.
- Severino is leaving to become CEO-Partner at a bioplatform innovation company and CEO of one of its portfolio companies.
- No replacement has been announced for Severino's roles at AbbVie.

## SEC filing metadata
- accession: 0001104659-22-045308
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000110465922045308/0001104659-22-045308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000110465922045308/tm2212581d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-045308
- JSON: https://secwatch.observer/filing/0001104659-22-045308.json
- Plain text: https://secwatch.observer/filing/0001104659-22-045308.txt

## Key facts
- Executive change
  Michael E. Severino departed as Vice Chairman and President at AbbVie Inc..
  - Action: departing
  - Role: Vice Chairman and President
  source text: On April 8, 2022, Michael E Severino informed AbbVie that he will be departing as AbbVie’s Vice Chairman and President, effective May 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000110465922045308/0001104659-22-045308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.